MedTrace Logo

Femoral Preincisional Block in Acute Postoperative Pain Management of Surgery Orthopaedic Lower Limb

NCT02239497 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2014-09-12

No results posted yet for this study

Summary

Proper management of acute postoperative pain (DAPO) is essential for the recovery of orthopedic surgeries. The blockade of the femoral nerve preincisional (BFP) is simple and its effectiveness increases guided by ultrasound and neurostimulation. OBJECTIVE: To evaluate the effectiveness of BFP in patients undergoing orthopedic surgery of the lower limbs under general anesthesia. METHODS: A comparative study was conducted, randomized, two groups, surgeries of the hip, femur and knee, ASA I-II, aged 18 years. Group B (n = 15) received BFP and ultrasound-guided nerve stimulation with 20 ml of bupivacaine 0.5% plus epinephrine 1: 200,000. Group S (n = 15) without blocking. Both groups received intravenous analgesia with ketoprofen 100 mg regimen and dipyrone 1g c / 8 hs and balanced general anesthesia. Postoperative morphine 0.03 mgr / kgr / weight was administered if EVA ≥4

Conditions

  • Surgery

Interventions

PROCEDURE

Femoral block by ultrasound and neurostimulation

DRUG

Intravenous analgesia

Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia

Sponsors & Collaborators

  • Hospital Central Dr. Luis Ortega

    lead OTHER

Principal Investigators

  • Beatriz S Arismendi Gomez, MD · Hospital "Dr Luis Ortega"

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2013-09-30

Countries

  • Venezuela

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02239497 on ClinicalTrials.gov